Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer-A Systematic Review and Network Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33561074/
The efficacy and safety of immune checkpoint inhibitors (ICIs) in refractory or relapsed advanced non-small-cell lung cancer (NSCLC) have not yet been compared with those of ramucirumab (Ram) plus docetaxel...
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08005-1
Background Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison...
57-Year-Old Never-Smoker with Dyspnea
Tom, a 57-year-old never-smoker, presented complaining of coughing, dyspnea, and fatigue. Other than mild hypertension controlled with losartan 100 mg, Tom has no comorbidities.
A chest X-ray reveals a mass in the left lung. Biopsy of the nodule was positive for non-small cell lung cancer and was an...
-
Alejandro Calvo5yrI would attempt a repeat biopsy or at least run a liquid biopsy to see if a resistance mutation can be identified, for example, if we identified G1202R mutation, Show More
-
Sumit Sawhney5yrpt with alk pos lung ca ,lorlatinib has marked brain penetration would consider lorlatinib ,though brigatinib and alcensa are other options
Show More Comments
LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33728331/
Lung cancer has a higher incidence rate and mortality rate than all other cancers. Early diagnosis and treatment of lung cancer remain a major challenge, and the 5-year survival rate...
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Source : https://clincancerres.aacrjournals.org/content/27/6/1631.abstract
Purpose: Tumor mutational burden (TMB) has been shown to be predictive of survival benefit in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Measuring TMB in...